--------------------------------------------------

---

The faster we get an approval the better. Unless you want to wait for HIV then COVID-19 is the answer. With what we know from CD-12 we can tailor CD16 and CD17 very specifically to try and achieve stat sig.

---

Let's not forget the long-hauler trial. As S. Kelly said, Covid-19 pales in comparison to long-haulers, or something to that effect. If 20-30% of recoverees end up with this condition that could be a very large market. Anecdotal 'tweets' have already been posted by those in trial who have received leronlimab and it's nothing short of a life saver for these people.